FY2017 Earnings Forecast for Aclaris Therapeutics, Inc. (ACRS) Issued By Jefferies Group

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Research analysts at Jefferies Group increased their FY2017 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued to investors on Tuesday. Jefferies Group analyst D. Steinberg now expects that the biotechnology company will post earnings per share of ($2.60) for the year, up from their prior forecast of ($3.28). Jefferies Group has a “Buy” rating and a $36.00 price target on the stock. Jefferies Group also issued estimates for Aclaris Therapeutics’ Q4 2017 earnings at ($0.92) EPS, FY2018 earnings at ($4.83) EPS, FY2019 earnings at ($2.88) EPS, FY2020 earnings at $0.52 EPS and FY2021 earnings at $2.18 EPS.

Several other brokerages also recently commented on ACRS. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research report on Tuesday, October 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price objective on shares of Aclaris Therapeutics in a research note on Monday, September 18th. BidaskClub raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. JMP Securities reaffirmed an “outperform” rating and set a $39.00 price target on shares of Aclaris Therapeutics in a research report on Friday, September 8th. Finally, ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. Aclaris Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $39.20.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.chaffeybreeze.com/2017/11/12/fy2017-earnings-forecast-for-aclaris-therapeutics-inc-acrs-issued-by-jefferies-group.html.

Shares of Aclaris Therapeutics (NASDAQ ACRS) opened at $23.23 on Friday. Aclaris Therapeutics has a 1-year low of $20.20 and a 1-year high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.23. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million.

A number of large investors have recently modified their holdings of ACRS. Wells Fargo & Company MN raised its position in Aclaris Therapeutics by 91.3% in the 1st quarter. Wells Fargo & Company MN now owns 12,359 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 5,900 shares during the period. Parametric Portfolio Associates LLC raised its position in Aclaris Therapeutics by 67.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 55,397 shares of the biotechnology company’s stock worth $1,652,000 after purchasing an additional 22,223 shares during the period. American International Group Inc. raised its position in Aclaris Therapeutics by 31.3% in the 1st quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 1,623 shares during the period. Alliancebernstein L.P. raised its position in Aclaris Therapeutics by 24.0% in the 1st quarter. Alliancebernstein L.P. now owns 9,300 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 1,800 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Aclaris Therapeutics by 57.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,320 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 2,680 shares during the period. Institutional investors own 95.85% of the company’s stock.

In related news, Director Andrew N. Schiff acquired 108,601 shares of the stock in a transaction dated Wednesday, August 16th. The shares were purchased at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 16.30% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply